Identification of LY2510924, a Novel Cyclic Peptide CXCR4 Antagonist That Exhibits Antitumor Activities in Solid Tumor and Breast Cancer Metastatic Models

Emerging evidence demonstrates that stromal cell-derived factor 1 (SDF-1) and CXCR4, a chemokine and chemokine receptor pair, play important roles in tumorigenesis. In this report, we describe a small cyclic peptide, LY2510924, which is a potent and selective CXCR4 antagonist currently in phase II clinical studies for cancer. LY2510924 specifically blocked SDF-1 binding to CXCR4 with IC50 value of 0.079 nmol/L, and inhibited SDF-1–induced GTP binding with Kb value of 0.38 nmol/L. In human lymphoma U937 cells expressing endogenous CXCR4, LY2510924 inhibited SDF-1–induced cell migration with IC50 value of 0.26 nmol/L and inhibited SDF-1/CXCR4-mediated intracellular signaling. LY2510924 exhibited a concentration-dependent inhibition of SDF-1–stimulated phospho-ERK and phospho-Akt in tumor cells. Biochemical and cellular analyses revealed that LY2510924 had no apparent agonist activity. Pharmacokinetic analyses suggested that LY2510924 had acceptable in vivo stability and a pharmacokinetic profile similar to a typical small-molecular inhibitor in preclinical species. LY2510924 showed dose-dependent inhibition of tumor growth in human xenograft models developed with non–Hodgkin lymphoma, renal cell carcinoma, lung, and colon cancer cells that express functional CXCR4. In MDA-MB-231, a breast cancer metastatic model, LY2510924 inhibited tumor metastasis by blocking migration/homing process of tumor cells to the lung and by inhibiting cell proliferation after tumor cell homing. Collectively, the preclinical data support further investigation of LY2510924 in clinical studies for cancer. Mol Cancer Ther; 14(2); 480–90. ©2014 AACR.

[1]  Yingying Wu,et al.  RNAi targeting CXCR4 inhibits tumor growth through inducing cell cycle arrest and apoptosis. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  R. Abagyan,et al.  Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists , 2010, Science.

[3]  N. Fujii,et al.  Peptide and peptidomimetic ligands for CXC chemokine receptor 4 (CXCR4). , 2012, Organic & biomolecular chemistry.

[4]  A. Viale,et al.  Epigenetic expansion of VHL-HIF signal output drives multi-organ metastasis in renal cancer , 2012, Nature Medicine.

[5]  H. Vogel,et al.  Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. , 2010, The Journal of clinical investigation.

[6]  F. Balkwill.  Cancer and the chemokine network , 2004, Nature Reviews Cancer.

[7]  J. Park,et al.  Multiple-Dose Escalation Study of the Safety, Pharmacokinetics, and Biologic Activity of Oral AMD070, a Selective CXCR4 Receptor Inhibitor, in Human Subjects , 2007, Antimicrobial Agents and Chemotherapy.

[8]  Ed Roos,et al.  The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. , 2003, Cancer research.

[9]  Andrew L Kung,et al.  A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[10]  R. Vij,et al.  A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. , 2012, Blood.

[11]  A. Nademanee,et al.  Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. , 2009, Blood.

[12]  Sheng-Bin Peng,et al.  Akt Activation, but not Extracellular Signal–Regulated Kinase Activation, Is Required for SDF-1α/CXCR4–Mediated Migration of Epitheloid Carcinoma Cells , 2005, Molecular Cancer Research.

[13]  G. Dranoff,et al.  CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. , 2011, Cancer research.

[14]  C. Creighton,et al.  CXCR4/CXCL12 Mediate Autocrine Cell- Cycle Progression in NF1-Associated Malignant Peripheral Nerve Sheath Tumors , 2013, Cell.

[15]  Ravi Salgia,et al.  Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. , 2002, Cancer research.

[16]  E. Galun,et al.  Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  N. Nadal,et al.  Prognostic value of CXCR4 and FAK expression in acute myelogenous leukemia. , 2009, Leukemia research.

[18]  M. Galsky,et al.  A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer , 2014, Clinical Cancer Research.

[19]  M. Uhlik,et al.  High-content multiplexed tissue imaging and quantification for cancer drug discovery. , 2013, Drug discovery today.

[20]  H. Sugerman,et al.  Association between Incident Cancer and Subsequent Stroke , 2015, Annals of neurology.

[21]  V. Wee Yong,et al.  CXCR4 Is a Major Chemokine Receptor on Glioma Cells and Mediates Their Survival* , 2002, The Journal of Biological Chemistry.

[22]  P. Chakravarty,et al.  An antagonist of the chemokine receptor CXCR4 induces mitotic catastrophe in ovarian cancer cells , 2009, Molecular Cancer Therapeutics.

[23]  D. McClure,et al.  Determination of [35S]guanosine-5'-O-(3-thio)triphosphate binding mediated by cholinergic muscarinic receptors in membranes from Chinese hamster ovary cells and rat striatum using an anti-G protein scintillation proximity assay. , 1999, The Journal of pharmacology and experimental therapeutics.

[24]  M. Konopleva,et al.  The CXCR4 Antagonist AMD3465 Regulates Oncogenic Signaling and Invasiveness In Vitro and Prevents Breast Cancer Growth and Metastasis In Vivo , 2013, PloS one.

[25]  J. Burger,et al.  CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells , 2005, Oncogene.

[26]  T. Mcclanahan,et al.  Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.

[27]  E. De Clercq,et al.  Determinants for Sensitivity of Human Immunodeficiency Virus Coreceptor CXCR4 to the Bicyclam AMD3100 , 1998, Journal of Virology.

[28]  J. Dipersio,et al.  Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[29]  Giovanni Martinelli,et al.  CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. , 2002, Cancer research.

[30]  A. Nagler,et al.  The High-Affinity CXCR4 Antagonist BKT140 Is Safe and Induces a Robust Mobilization of Human CD34+ Cells in Patients with Multiple Myeloma , 2013, Clinical Cancer Research.

[31]  Dominique Schols,et al.  Safety, Pharmacokinetics, and Antiviral Activity of AMD3100, a Selective CXCR4 Receptor Inhibitor, in HIV-1 Infection , 2004, Journal of acquired immune deficiency syndromes.

[32]  E. Su,et al.  Identification and expression of novel isoforms of human stromal cell-derived factor 1. , 2006, Gene.

[33]  M. Seshadri,et al.  Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases , 2013, Proceedings of the National Academy of Sciences.

[34]  R. Ganju,et al.  The α-Chemokine, Stromal Cell-derived Factor-1α, Binds to the Transmembrane G-protein-coupled CXCR-4 Receptor and Activates Multiple Signal Transduction Pathways* , 1998, The Journal of Biological Chemistry.

[35]  Dennis C. Sgroi,et al.  Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion , 2005, Cell.

[36]  H. Moch,et al.  Chemokine receptor CXCR4 downregulated by von Hippel–Lindau tumour suppressor pVHL , 2003, Nature.

[37]  E. D. de Vries,et al.  A review on CXCR4/CXCL12 axis in oncology: no place to hide. , 2013, European journal of cancer.

[38]  D. Piwnica-Worms,et al.  CXCR4 Regulates Growth of Both Primary and Metastatic Breast Cancer , 2004, Cancer Research.

[39]  Derek S. Chan,et al.  Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer , 2013, Proceedings of the National Academy of Sciences.

[40]  Nouri Neamati,et al.  Small Molecule Inhibitors of CXCR4 , 2013, Theranostics.